Specialty Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
36.7 /100
Rank 89 out of 131 Industries -
Advance/Decline
20/5
-
No. of Companies25
-
Avg. Market Cap1,798
-
Price to Earning Ratio16.89
-
Price to Earning Growth Ratio0.14
-
Price to Book Ratio5.78
-
Return on Equity17.00
-
Return on Capital Employed-
-
Return on Assets15.03
-
Dividend yield 1 year %0.00
-
Net Profit Growth Annual YoY %84.65 %
-
Net Profit Growth Qtr YoY %266.41 %
-
Net Profit Growth Qtr QoQ %778.50 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Specialty Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Specialty Pharmaceuticals Peer comparison
Compare all stocks in Specialty Pharmaceuticals industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Usana Health Sciences Inc |
|
466.6
|
24.7
|
L
H
23.9
24.8
|
L
 -2.9%
H
23.7
26.4
|
L
 -23.9%
H
23.7
32.6
|
L
 -27.0%
H
23.7
36.3
|
L
 -43.7%
H
23.7
49.8
|
L
 -70.1%
H
23.7
83.8
|
L
 -64.0%
H
23.7
107.9
|
L
 -58.2%
H
23.7
138.0
|
Argen X SE - ADR |
|
35,432.0
|
580.9
|
L
 6.4%
H
570.3
586.2
|
L
 4.7%
H
519.8
586.2
|
L
 -1.8%
H
519.8
627
|
L
 -11.5%
H
519.8
678.2
|
L
 53.7%
H
352.8
678.2
|
L
 81.5%
H
267.3
678.2
|
L
 304.6%
H
130
678.2
|
L
H
17.3
678.2
|
Cidara Therapeutics Inc |
|
199.4
|
18.2
|
L
 6.5%
H
16.7
18.3
|
L
 10.8%
H
15.2
18.5
|
L
 -20.9%
H
15.2
23.8
|
L
 -24.2%
H
15.2
25.8
|
L
 -94.4%
H
10
352
|
L
 -94.0%
H
10
840
|
L
 -98.2%
H
10
1780
|
L
H
10
7652
|
Niagen Bioscience Inc. |
|
461.1
|
5.9
|
L
 4.6%
H
5.6
5.9
|
L
 -1%
H
5.3
6.2
|
L
 -24.3%
H
5.3
8
|
L
 11.3%
H
5.2
9.2
|
L
 54.0%
H
2.3
9.2
|
L
 175.8%
H
1.2
9.2
|
L
 70.4%
H
1.2
23.7
|
L
 42.2%
H
1.2
23.7
|
Cronos Group Inc |
|
669.4
|
1.8
|
L
 4.2%
H
1.7
1.8
|
L
 2.3%
H
1.6
1.8
|
L
 -7.9%
H
1.6
1.9
|
L
 -11.6%
H
1.6
2.1
|
L
 -31.1%
H
1.6
3.1
|
L
 -48.8%
H
1.6
3.6
|
L
 -69.8%
H
1.6
15.8
|
L
H
0.2
25.1
|
Cyanotech Corp. |
|
2.3
|
0.3
|
L
 6.7%
H
0.3
0.3
|
L
 -11.1%
H
0.3
0.4
|
L
 -13.5%
H
0.3
0.4
|
L
 -20%
H
0.3
0.4
|
L
 -3.0%
H
0.3
0.9
|
L
 -89.5%
H
0.1
3.6
|
L
 -85.5%
H
0.1
6.3
|
L
 -96.7%
H
0.1
10.9
|
Enveric Biosciences Inc |
|
2.4
|
1.3
|
L
 6.8%
H
1.2
1.3
|
L
 3.3%
H
1.0
1.3
|
L
 -26.5%
H
1.0
1.9
|
L
 212.5%
H
0.3
4.8
|
L
 37.4%
H
0.3
4.8
|
L
 -91.4%
H
0.3
18.5
|
L
 -99.2%
H
0.3
1060
|
L
 -100.0%
H
0.3
67500
|
Flora Growth Corp |
|
8.9
|
0.5
|
L
H
0.5
0.5
|
L
 -6.1%
H
0.4
0.5
|
L
 -25.8%
H
0.4
0.7
|
L
 -52.1%
H
0.4
1.1
|
L
 -79.2%
H
0.4
2.2
|
L
 -98.7%
H
0.4
35.6
|
L
H
0.4
429
|
L
H
0.4
429
|
IM Cannabis Corp |
|
4.2
|
1.4
|
L
 3.8%
H
1.4
1.4
|
L
H
1.3
1.6
|
L
 -23.9%
H
1.3
2.0
|
L
 -43.9%
H
1.3
2.7
|
L
 -68.6%
H
0.4
7.9
|
L
 -98.9%
H
0.4
132
|
L
H
0.4
697.8
|
L
H
0.4
697.8
|
Lifevantage Corporation |
|
177.5
|
14.1
|
L
 2.3%
H
13.0
14.8
|
L
 -1.3%
H
13.0
15.4
|
L
 -9.9%
H
13.0
17.6
|
L
 -37.1%
H
13.0
27.4
|
L
 132.6%
H
5.2
27.4
|
L
 205.4%
H
3.0
27.4
|
L
 19.4%
H
3.0
27.4
|
L
 190.9%
H
1.4
27.4
|
Mannatech Inc |
|
18.8
|
10.0
|
L
 19%
H
8.4
10.7
|
L
 19.3%
H
8.4
10.7
|
L
 -9.2%
H
7.7
11.2
|
L
 -33.5%
H
7.7
16.5
|
L
 19.9%
H
6.8
16.5
|
L
 -70.8%
H
6.8
35.5
|
L
 -0.2%
H
6.8
49.1
|
L
 -52.0%
H
6.5
49.1
|
Natural Alternatives Inter... |
|
18.3
|
3.0
|
L
 -1.7%
H
2.8
3.3
|
L
 -10.9%
H
2.8
3.3
|
L
 -10.1%
H
2.8
3.9
|
L
 -29.9%
H
2.8
4.3
|
L
 -56.0%
H
2.8
7.3
|
L
 -74.4%
H
2.8
12.6
|
L
 -55.6%
H
2.8
19.9
|
L
 -45.8%
H
2.8
19.9
|
Nature`s Sunshine Products... |
|
222.7
|
12.1
|
L
 3.0%
H
11.5
12.2
|
L
 2.3%
H
11.0
12.6
|
L
 -16.9%
H
11.0
14.3
|
L
 -15.3%
H
11.0
15.3
|
L
 -37.7%
H
10.8
19.9
|
L
 -31.5%
H
7.9
21.7
|
L
 47.1%
H
7.5
21.7
|
L
 -4.3%
H
5.5
21.7
|
Paranovus Entertainment Te... |
|
89.6
|
1.3
|
L
 -0.8%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -3.6%
H
1.3
1.4
|
L
H
1.2
1.5
|
L
 -7.0%
H
0.3
1.5
|
L
 -78.2%
H
0.3
6.8
|
L
 -97.7%
H
0.3
73.6
|
L
H
0.3
122
|
PharmaCyte Biotech Inc |
|
8.4
|
1.2
|
L
 7.9%
H
1.2
1.2
|
L
 -0.8%
H
1.1
1.3
|
L
 -30.1%
H
1.1
1.8
|
L
 -19.1%
H
1.1
1.9
|
L
 -46.5%
H
1.1
2.5
|
L
 -43.3%
H
1.1
3.2
|
L
 -97.3%
H
1.1
55.5
|
L
 -99.4%
H
1.1
392.3
|
ProPhase Labs Inc |
|
13.0
|
0.3
|
L
 14.8%
H
0.3
0.3
|
L
 29.2%
H
0.2
0.5
|
L
 -16.2%
H
0.2
0.6
|
L
 -52.3%
H
0.2
0.8
|
L
 -95.2%
H
0.2
7.5
|
L
 -96.2%
H
0.2
15.3
|
L
 -82.8%
H
0.2
16.0
|
L
 -77.2%
H
0.2
16.0
|
Qualigen Therapeutics Inc |
|
2.2
|
3
|
L
 -1.6%
H
2.9
3.3
|
L
 -4.2%
H
2.9
3.4
|
L
 -1.3%
H
2.9
4.0
|
L
 -29.9%
H
2.9
4.6
|
L
 -83.6%
H
0.1
29.4
|
L
 -99.0%
H
0.1
760
|
L
 -99.9%
H
0.1
9875
|
L
H
0.1
687487.5
|
Revolution Medicines Inc |
|
6,640.8
|
35.7
|
L
 6.1%
H
33.3
35.9
|
L
 14.1%
H
29.2
35.9
|
L
 -8.2%
H
29.2
40.9
|
L
 -14.5%
H
29.2
44.7
|
L
 -4.5%
H
29.2
62.4
|
L
 51.7%
H
14.1
62.4
|
L
 51.0%
H
14.1
62.4
|
L
H
14.1
62.4
|
Smart for Life Inc |
|
-
|
0
|
L
H
0
0
|
L
H
0
0
|
L
 -100%
H
0
0.0
|
L
 -100%
H
0.0
|
L
 -100%
H
26.7
|
L
 -100%
H
4284
|
L
H
10237.5
|
L
H
10237.5
|
Upexi Inc |
|
3.4
|
2.6
|
L
 9.9%
H
2.3
2.6
|
L
 26.7%
H
1.9
2.6
|
L
 -6.2%
H
1.9
2.7
|
L
 -33.5%
H
1.9
6.1
|
L
 -74.9%
H
1.9
15.9
|
L
 -97.2%
H
1.9
121.6
|
L
H
1.9
187.4
|
L
H
1.9
187.4
|
Scinai Immunotherapeutics ... |
|
1.8
|
2.0
|
L
 -10.9%
H
1.9
2.4
|
L
 -22.5%
H
1.9
2.9
|
L
 -40.6%
H
1.9
3.9
|
L
 -44.5%
H
1.9
4.0
|
L
 -59.2%
H
1.9
46.9
|
L
 -98.8%
H
1.9
176
|
L
 -99.7%
H
1.9
6200
|
L
H
1.9
6200
|
FitLife Brands Inc |
|
107.8
|
11.7
|
L
 0.5%
H
11.6
12.3
|
L
 12.4%
H
9.8
12.5
|
L
 -15.0%
H
9.8
14.9
|
L
 -60.7%
H
9.8
33.5
|
L
 -58.7%
H
9.8
35.5
|
L
 -29.4%
H
9.8
35.5
|
L
 -29.4%
H
9.8
35.5
|
L
 -29.4%
H
9.8
35.5
|
Abivax - ADR |
|
378.6
|
6.0
|
L
 6.8%
H
5.5
6.1
|
L
 12.2%
H
4.8
6.3
|
L
 -5.8%
H
4.8
7.9
|
L
 -6.4%
H
4.8
8.5
|
L
 -60.2%
H
4.8
16.6
|
L
H
4.8
17.0
|
L
H
4.8
17.0
|
L
H
4.8
17.0
|
Synergy CHC Corp |
|
15.3
|
1.8
|
L
 1.7%
H
1.7
1.9
|
L
 -22.6%
H
1.3
2.5
|
L
 -45.4%
H
1.3
3.7
|
L
H
1.3
4.6
|
L
H
1.3
4.6
|
L
H
1.3
4.6
|
L
H
1.3
4.6
|
L
H
1.3
4.6
|
iBio Inc |
|
-
|
1.2
|
L
 -0.8%
H
1.1
1.3
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|
L
H
|